FDA accepts Exelixis treatment for priority review
07:41 EDT 30 Jul 2012 | R&D Magazine
SOUTH SAN FRANCISCO, Calif. (AP) — Drug developer Exelixis Inc. said Monday that the Food and Drug Administration has accepted its potential thyroid cancer treatment, carbozantinib, for priority review.The drug aims to treat an advanced form of med..
Original Article: FDA accepts Exelixis treatment for priority review
More From BioPortfolio on "FDA accepts Exelixis treatment for priority review"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
